早期激素受体阳性乳腺癌质子部分乳腺放疗后的结局与毒性:II期多中心试验3年结果
这项II期多中心试验纳入38例≥50岁、淋巴结阴性、ER阳性、肿瘤≤3cm的早期乳腺癌患者,接受质子部分乳腺照射40 Gy(RBE)/10次。中位随访35个月,无同侧乳腺复发,无≥3级放疗相关毒性,患者报告生活质量无有意义变化。
要点
- 质子部分乳腺照射40 Gy(RBE)/10次,3年同侧乳腺复发率为0%。
- 无放疗相关≥3级毒性,仅7例次2级不良事件。
- BCTOS各亚域均值变化最大0.36,患者报告生活质量无有意义变化。
核心结论
- 3年时质子部分乳腺照射对早期ER阳性乳腺癌提供100%肿瘤控制,毒性极小,患者报告生活质量保持可接受,这些发现支持质子治疗作为安全有效的部分乳腺照射实施选项。
研究设计与样本
- 质子协作组II期多中心试验(PCG BRE007-12)前瞻性纳入38例可评估女性患者,年龄≥50岁,淋巴结阴性、ER阳性、肿瘤≤3cm的浸润性导管癌或导管原位癌,接受保乳手术后质子部分乳腺照射40 Gy(RBE),10次每日照射。
主要发现
- 患者于2013年2月至2016年11月入组,中位年龄67岁(范围50-79),55%为左侧病变,中位肿瘤大小0.9 cm。
- 中位随访35个月(范围12-62),全部患者存活,无局部、区域或远处疾病进展,1例患者发生ER阴性对侧浸润性导管癌。
- 发生7例次2级不良事件,无放疗相关≥3级毒性。
- BCTOS各亚域平均评分变化最大为0.36,表明患者报告生活质量无有意义变化。
- 中位心脏V5Gy为0%,肺V20Gy为0%,肺V10Gy为0.19%。
临床怎么用
- 原文结论指出这些发现支持质子治疗作为安全有效的部分乳腺照射实施选项。
局限性
- 原文结论提及需继续随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Proton therapy (PT) for partial breast irradiation (PBI) in early-stage breast cancer can decrease morbidity versus photon PBI with superior organs-at-risk sparing. We report 3-year outcomes of the first prospective, multicenter, phase II trial of proton PBI. METHODS AND MATERIALS: This Proton Collaborative Group phase II trial (PCG BRE007-12) recruited women ≥ 50 years with node-negative, estrogen receptor (ER)-positive, ≤3cm, invasive ductal carcinoma (IDC) or ductal carcinoma in situ undergoing breast conserving surgery followed by proton PBI (40 Gy(RBE), 10 daily fractions). Primary endpoint was freedom from ipsilateral breast cancer recurrence. Adverse events were prospectively graded using CTCAEv4.0. Breast Cancer Treatment Outcome Scale (BCTOS) assessed patient-reported quality of life (PRQOL). RESULTS: Thirty-eight evaluable patients enrolled between 2/2013-11/2016. Median age was 67 years (range 50-79); 55 % had left-sided disease, and median tumor size was 0.9 cm. Treatment was delivered in ≥ 2 fields predominantly with uniform scanning PT (n = 37). At 35-month median follow-up (12-62), all patients were alive, and none had local, regional or distant disease progression. One patient developed an ER-negative contralateral IDC. Seven grade 2 adverse events occurred; no radiotherapy-related grade ≥ 3 toxicities occurred. Changes in BCTOS subdomain mean scores were maximum 0.36, indicating no meaningful change in PRQOL. Median heart volume receiving 5 Gy (V5Gy), lung V20Gy, and lung V10Gy were 0 %, 0 % and 0.19 %, respectively. CONCLUSION: At 3 years, proton PBI provided 100 % cancer control for early-stage, ER-positive breast cancer. Toxicities are minimal, and PRQOL remains acceptable with continued follow-up. These findings support PT as a safe and effective PBI delivery option.
引用
- Choi JI, Prabhu K, Hartsell WF, et al. Outcomes and toxicities after proton partial breast radiotherapy for early stage, hormone receptor positive breast cancer: 3-Year results of a phase II multi-center trial. Clin Transl Radiat Oncol. 2022. PMID: 36093343. doi:10.1016/j.ctro.2022.08.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。